Skip to main content
. 2023 Jun 4;13(9):2012–2031. doi: 10.1158/2159-8290.CD-23-0475

Figure 5.

Figure 5. Clinical response in an FGFRi-naive iCCA patient with liver and lymph node metastases. The patient was treated with RLY-4008 at 70 mg once daily, the RP2D. A, Summary of key patient and disease characteristics. B, CT scans of liver and lymph node metastases at baseline (top) and after 163 days of RLY-4008 treatment (bottom) show profound tumor regression. C, Serum phosphate over the course of treatment with RLY-4008. The shaded area represents the normal range for serum phosphate (0.8–1.5 mmol/L). q.d., once daily; RP2D, recommended phase II dose.

Clinical response in an FGFRi-naive iCCA patient with liver and lymph node metastases. The patient was treated with RLY-4008 at 70 mg once daily, the RP2D. A, Summary of key patient and disease characteristics. B, CT scans of liver and lymph node metastases at baseline (top) and after 163 days of RLY-4008 treatment (bottom) show profound tumor regression. C, Serum phosphate over the course of treatment with RLY-4008. The shaded area represents the normal range for serum phosphate (0.8–1.5 mmol/L). q.d., once daily; RP2D, recommended phase II dose.